Tumor Biology

, Volume 37, Issue 1, pp 305–311 | Cite as

Salinomycin radiosensitizes human nasopharyngeal carcinoma cell line CNE-2 to radiation

  • Yongqin Zhang
  • Yun Zuo
  • Zhifeng Guan
  • Weidong Lu
  • Zheng Xu
  • Hao Zhang
  • Yan Yang
  • Meilin Yang
  • Hongcheng Zhu
  • Xiaochen Chen
Research Article

Abstract

Nasopharyngeal carcinoma (NPC) is primarily treated by chemoradiation. However, how to promote radiation sensitivity in NPC remains a challenge. Salinomycin is potentially useful for the treatment of cancer. This study aimed to explore the radiosensitivity of salinomycin on human nasopharyngeal carcinoma cell line CNE-2. CNE-2 were treated with salinomycin or irradiation, alone or in combination. The cytotoxicity effects of salinomycin were measured using CCK-8 assay. Clonogenic survival assay was used to evaluate the effects of salinomycin on the radiosensitivity of CNE-2. The changes of cell cycle distribution and apoptosis were assayed using flow cytometry. The expression of Caspase3/Bax/Bal-2 was detected by Western blotting. DNA damage was detected via γ-H2AX foci counting. The results showed that salinomycin induced apoptosis and G2/M arrest, increased Bax and cleaved Caspase3, decreased Bcl-2 expression, and increased the formation of γ-H2AX nuclear foci. These data suggest that salinomycin may be a radiosensitizer for NPC radiotherapy.

Keywords

Salinomycin Nasopharyngeal carcinoma Radiosensitization 

References

  1. 1.
    Akervall J, Nandalur S, Zhang J, Qian CN, Goldstein N, Gyllerup P, et al. A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 2014;50(3):570–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O, Hirsoe C. Salinomycin, a new polyether antibiotic. J Antibiot Tokyo. 1974;27(11):814–21.CrossRefPubMedGoogle Scholar
  3. 3.
    Mahmoudi N, de Julián-Ortiz JV, Ciceron L, Gálvez J, Mazier D, Danis M, et al. Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening. J Antimicrob Chemother. 2006;57(3):489–97.CrossRefPubMedGoogle Scholar
  4. 4.
    Danforth HD, Ruff MD, Reid WM, Johnson J. Anticoccidial activity of salinomycin in floor-pen experiments with broilers. Poult Sci. 1977;56(3):933–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645–59.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zhi QM, Chen XH, Ji J, Zhang JN, Li JF, Cai Q, et al. Salinomycin can effectively kill ALDH (high) stem-like cells on gastric cancer. Biomed Pharmacother. 2011;65(7):509–15.CrossRefPubMedGoogle Scholar
  7. 7.
    He L, Wang F, Dai WQ, Wu D, Lin CL, Wu SM, et al. Mechanism of action of salinomycin on growth and migration in pancreatic cancer cell lines. Pancreatology. 2013;13(1):72–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang GN, Liang Y, Zhou LJ, Chen SP, Chen G, Zhang TP, et al. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett. 2011;313(2):137–44.CrossRefPubMedGoogle Scholar
  9. 9.
    Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, et al. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 2012;7(12):e50638.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhang B, Wang X, Cai F, Chen W, Loesch U, Bitzer J, et al. Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK. Tumour Biol. 2012;33(6):1855–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää AL, Orešič M, et al. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 2012;106(1):99–106.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kim KY, Yu SN, Lee SY, Chun SS, Choi YL, Park YM, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 2011;413(1):80–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Kuo SZ, Blair KJ, Rahimy E, Kiang A, Abhold E, Fan JB, et al. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer. 2012;12:556.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Scherzed A, Hackenberg S, Froelich K, Rak K, Technau A, Radeloff A, et al. Effects of salinomycin on human bone marrow-derived mesenchymal stem cells in vitro. Toxicol Lett. 2013;218(3):207–14.CrossRefPubMedGoogle Scholar
  15. 15.
    Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009;390(3):743–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010;394(4):1098–104.CrossRefPubMedGoogle Scholar
  17. 17.
    Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis. 2010;45(1):86–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang Y. Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med Chem. 2011;7(2):106–11.CrossRefPubMedGoogle Scholar
  19. 19.
    Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH. Salinomycin selectively targets ‘CD133+’ cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol. 2011;18(6):1797–804.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang C, Yang X, Zhang Q, Yang B, Xu L, Qin Q, et al. Berberine radiosensitizes human nasopharyngeal carcinoma by suppressing hypoxia-inducible factor-1α expression. Acta Otolaryngol. 2014;134:185–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, et al. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol. 2011;162(3):773–84.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Verdoodt B, Vogt M, Schmitz I, Liffers ST, Tannapfel A, Mirmohammadsadegh A. Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species. PLoS One. 2012;7(9):e44132.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54f28. Pharmacol Ther. 2015;146:1–11.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yongqin Zhang
    • 1
  • Yun Zuo
    • 1
  • Zhifeng Guan
    • 2
  • Weidong Lu
    • 1
  • Zheng Xu
    • 1
  • Hao Zhang
    • 3
  • Yan Yang
    • 3
  • Meilin Yang
    • 3
  • Hongcheng Zhu
    • 3
  • Xiaochen Chen
    • 3
  1. 1.Department of Radiation OncologyThe First People’s Hospital of ZhangjiagangZhangjiagangChina
  2. 2.Department of Radiation Oncology, Nantong Tumor HospitalAffiliated Tumor Hospital of Nantong UniversityNantongChina
  3. 3.Department of Radiation OncologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina

Personalised recommendations